This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Thrombolysis  • Neurology  • Cerebrovascular Disease  • Stroke  • Cardiovascular System  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The CREATE trial¹ demonstrated an overall lower rate of hemorrhagic stroke among patients treated with reviparin (0.3%) vs that reported in previous trials of unfractionated heparin and enoxaparin,^2-3 and the National Registry of Myocardial Infarction 2 trial.⁴ Although this finding may represent differences in pharmacological properties of reviparin and the dosing regimens, the lower age and systolic blood pressure of the study population vs that of other STEMI trials, together with the exclusion of patients at high risk of bleeding, may also have contributed to the low rate of this serious complication. Furthermore, the patients enrolled in China were older (mean age, 62.7 years) than patients from other countries but were also less likely to receive fibrinolytic therapy (52%).⁵ Therefore, although the CREATE trial established the role of antithrombotic therapy as an adjunct to fibrinolytics in STEMI, the optimal agent and dose remain to be determined.

. . . [Full Text of this Article]

Andrew T. Yan, MD; Raymond T. Yan, MD; Shaun G. Goodman, MD, MSc
goodmans@smh.toronto.on.ca
St Michael’s Hospital
University of Toronto
Toronto, Ontario

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Reviparin in Acute Myocardial Infarction

JAMA. ;293():2595-2595.
FULL TEXT  

Reviparin in Acute Myocardial Infarction--Reply
, , and
JAMA. ;293():2595-2596.
FULL TEXT  

Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation

JAMA. ;293():427-435.
FULL TEXT